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Abstract
Background: Despite the utility of neuroimaging in the diagnostic and therapeutic management of patients with
acute ischemic stroke (AIS), imaging characteristics in patients with preceding direct oral anticoagulants (DOAC)
compared to vitamin K antagonists (VKA) have hardly been described. We aimed to determine presence of large
vessel occlusion (LVO), thrombus length, infarction diameter, and occurrence of hemorrhagic transformation in AIS
patients with preceding DOAC as compared to VKA therapy.
Methods: Using a prospectively collected cohort of AIS patients, we performed univariate and multivariable
regression analyses regarding imaging outcomes. Additionally, we provide a sensitivity analysis for the subgroup of
patients with confirmed therapeutic anticoagulation.
Results: We included AIS in patients with preceding DOAC (N = 75) and VKA (N = 61) therapy, median age 79 (IQR
70–83), 39% female. Presence of any LVO between DOAC and VKA patients (29.3% versus 37.7%, P = 0.361), and
target LVO for endovascular therapy (26.7% versus 27.9%, P = 1.0) was equal with a similar occlusion pattern. DOAC
as compared to VKA were associated with a similar rate of target LVO for EVT (aOR 0.835, 95% CI 0.368–1.898). The
presence of multiple lesions and characteristics of the thrombus were similar in DOAC and VKA patients. Acute
ischemic lesion diameter in real world patients was equal in patients taking DOAC as compared to VKA. Lesion
diameter in VKA patients (median 13 mm, IQR 6–26 versus median 20 mm, IQR 7–36, P = 0.001), but not DOAC
patients was smaller in the setting of confirmed therapeutic VKA. The frequency of radiological hemorrhagic
transformation and symptomatic intracranial hemorrhage in OAC patients was low. Sensitivity analysis considering
only patients with confirmed therapeutic anticoagulation did not change any of the results.
Conclusion: Preceding DOAC treatment showed equal rates of LVO and infarct size as compared to VKA in AIS
patients. This study adds to the knowledge of imaging findings in AIS patients with preceding anticoagulation.
Keywords: Acute ischemic stroke, DOAC, VKA, Large vessel occlusion, Anticoagulation, Infarction size, Hemorrhagic
transformation
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Background
Patients with atrial fibrillation (AF) have a five-fold in-
creased risk of acute ischemic stroke (AIS). Therefore, oral
anticoagulation (OAC) is recommended after risk stratifi-
cation to prevent thromboembolic events [1]. Due to the
increased risk of intracerebral hemorrhage and downsides
of management of Vitamin K antagonists (VKA), direct
oral anticoagulants (DOAC) are now recommended as
first line OAC in patients with AF [1, 2]. Even with the
pronounced preventive reduction of AIS by OAC [1], AIS
occurs with an estimated rate of about 1–2% per year in
patients taking a DOAC [3].
Initial imaging in AIS is crucial to rapidly obtain an ac-
curate diagnosis, select patients for acute recanalization
treatments, predict outcome, guide etiological work-up and
initiate early secondary prevention [4–6]. Nevertheless, data
on imaging characteristics of AIS in patients taking OAC,
especially DOAC are sparse [7, 8]. Few comparative small
studies looked at size, volume and presence of a large vessel
occlusion (LVO) [9, 10] in patients taking DOAC versus
VKA, with preliminary results in favor of DOAC. However,
no laboratory assessment of OAC activity or information
on compliance for DOAC was available.
Hence, we aimed to explore the frequency of any LVO
or target LVO for endovascular stroke treatment and
other imaging characteristics of AIS in a prospectively
collected registry of patients admitted to our compre-
hensive university stroke center prescribed with OAC.
Additionally, we present a sensitivity analysis considering
only patients with confirmed therapeutic DOAC and
VKA activity on admission.
Methods
Inclusion criteria for this study were a diagnosis of AIS
and preceding OAC prescription at the time point of
symptom onset (either DOAC or VKA). We selected a
random sample of patients fulfilling the inclusion criteria
from our prospectively consecutive local stroke registry
from February 2015 to August 2017. We chose random
sampling because of lack of capacity to analyze the im-
ages of all DOAC and VKA patients of the registry. For
this purpose, a random number between 0 and 1 was
generated using the excel function = RAND for each pa-
tient. By sorting the random number ascendingly, the
first 80 patients were included in the study. We analyzed
only patients with MRI on admission, which represents
the preferred imaging modality in our center (about 60–
70%). We excluded patients with transient ischemic
attacks, stroke mimics, non-cerebral ischemic events, re-
fusal of further use of biological data and missing infor-
mation on OAC medication from this analysis.
Antiplatelet prescription did not affect group assign-
ment. For the sensitivity analysis, we further defined
confirmed therapeutic OAC as specific drug activity >
50 ng/ml in patients taking DOAC [11–15] and INR >
1.7 in VKA patients. If no specific drug activity was
available in patients taking DOAC, confirmed thera-
peutic OAC was defined as reported previously [16].
We assessed the following information from the registry
and in case of missing items in the medical records: demo-
graphic variables (age, sex, prestroke modified Rankin Scale
(mRS)), cardiovascular risk factors, clinical parameters
(blood pressure, National Institutes of Health Stroke Scale
(NIHSS), onset type, TOAST-etiology, antithrombotic, an-
tihypertensive and lipid lowering medication before admis-
sion, laboratory parameters (cholesterol, glucose, creatinine,
and international normalized ratio INR) and acute recanali-
zation treatment such as intravenous thrombolysis (IVT)
and endovascular therapy (EVT).
Imaging protocol
We acquired MRI scans on the day of admission, either
on a 1.5 T scanner (Siemens Magnetom Avanto and Sie-
mens Magnetom Aera, Siemens Medical Solutions, Er-
langen, Germany) or a 3 T system (Siemens Magnetom
Verio, Siemens Medical Solutions, Erlangen, Germany).
Our MRI protocol includes axial diffusion-weighted im-
aging (DWI) with apparent diffusion coefficient (ADC) (5
mm slice thickness), Fluid-attenuated inversion recovery
(FLAIR) (5mm slice thickness), susceptibility-weighted
imaging (SWI) (1.6mm slice thickness), and a time of
flight (TOF) angiography (0.5mm slice thickness). After
application of intravenous Gadobutrol (Gadovist; Bayer
Schering Pharma, Berlin, Germany) in an antecubital vein
with a 5ml/s injection rate, we acquired a standard dy-
namic susceptibility contrast (DSC) MRI perfusion (Tmax,
5mm slice thickness) as well as a contrast enhanced T1-
weighted sequence (slice thickness 5mm). Finally, a con-
trast enhanced magnetic resonance angiography (CE
MRA) of the head and neck vessels was acquired after in-
jection of a second bolus of Gadobutrol with a 3ml/s in-
jection rate. Post-processing of DSC was performed using
Olea sphere v.2.3 (Olea Medical, La Ciotat, France), using
deconvolution method with oscillant singular value de-
composition. Follow-up imaging was performed using the
same scanners and same MRI protocol.
Outcomes and imaging analysis
Two raters (EA and SF) assessed the imaging outcomes
after a standardized training and blinded to patients’ OAC
status. All ratings were controlled by a board-certified neu-
roradiologist (AH) with more than 10 years’ experience in
stroke imaging. The primary outcome was the presence of
any LVO defined as occlusion of an artery supplying the
brain visible on TOF or contrast enhanced MR-
angiography. Secondary outcomes included: target LVO for
EVT defined as LVO until or proximal to A1/M2-segment
of the anterior circulation or P1-segment of the posterior
Meinel et al. BMC Neurology           (2020) 20:86 Page 2 of 8
circulation; presence and length of thrombus as determined
by SWI; size of hypoperfusion; degree of DWI infarction
core and hypoperfused area mismatch defined as small mis-
match (infarction core ≥2/3 of the hypoperfused region),
moderate mismatch (infarction core > 1/3 and < 2/3 of the
hypoperfused region) and large mismatch (infarction core
≤1/3 of the hypoperfused region) by visual judgment;
maximal diameter in mm of the acute ischemic lesion as
determined in DWI (axis 1), maximal diameter of a perpen-
dicular axis of the acute ischemic lesion (axis 2). In case of
multiple lesions, the largest lesion was analyzed for the pri-
mary analysis. Other outcomes included size of ischemia
demarcation in FLAIR sequence at 24 h; presence of cere-
bral microbleeds (CMB) according to established criteria at
baseline [17]; presence of hemorrhagic transformation at
24 h according to the Heidelberg classification [18]; pres-
ence of more than one (multiple) acute ischemic lesions
and severity of white matter hyperintensities according to
the Fazekas score [19].
Statistics
We compared the two OAC groups (DOAC versus VKA),
and patients with confirmed and infra-therapeutic OAC
using appropriate statistical measures (Fisher’s exact test
for categorical variables, Mann-Whitney-U-Test for non-
normally continuous or ordinally scaled variables, and
Welch’s t-test for independent normally distributed data).
We determined published predictors of stroke severity as
pre-specified covariates and factors for the multivariate
analysis avoiding collinearity. For the primary analysis, the
association of OAC type (DOAC versus VKA) with any
LVO or target LVO for EVT was assessed using binary lo-
gistic regression adjusting for the following confounders:
age (continuous), sex (categorical), admission glucose (lin-
ear, adjusted odds ratio (aOR) per mmol/L increase), ar-
terial hypertension (categorical) and atrial fibrillation
(categorical). For the secondary analysis, the same con-
founders were included in a multivariable linear regression
analysis. Patients with missing data items were excluded
from the multivariate analysis. For the sensitivity analysis,
the same model was used considering only patients with
confirmed therapeutic OAC activity on admission. We
used a level of significance of 0.05.
Results
The random sample of OAC patients with AIS fulfilling
the in- and exclusion criteria included 75 DOAC patients
(59 Rivaroxaban, 12 Apixaban, 4 Dabigatran) and 61 VKA
patients. Either documented information on compliance
or a reliable assessment of DOAC activity was available in
45/75 (60%) of patients taking DOAC. INR was available
in all patients taking VKA. OAC activity was confirmed
therapeutic in 35/75 (46.7%) of DOAC patients and 45/61
(73.8%) of VKA patients. Table 1 summarizes the
demographic and clinical data of the patients. Patients with
preceding DOAC prescription were younger and had less
severe white matter lesions as compared to VKA patients.
Otherwise, groups were comparable for baseline and treat-
ment variables.
There was no difference in the frequency of any LVO
between DOAC and VKA patients (29.3% versus 37.7%,
P = 0.361) on univariate analysis. There was also no differ-
ence in target LVO for EVT between DOAC and VKA
patients (26.7% versus 27.9%, P = 1.0), but the size of the
initial hypoperfusion was significantly larger in DOAC pa-
tients (80mm, IQR 38–118 versus 49mm, IQR 36–67;
P = 0.039). The occlusion pattern was similar in patients
with DOAC and VKA (Table 2) without a signal for more
proximal or distal occlusions in either group. Equally, on
binary logistic regression analysis DOAC as compared to
VKA was not associated with the presence of any LVO
(aOR 0.622, 95% CI 0.283–1.366) or presence of a target
LVO for EVT (aOR 0.835, 95% CI 0.368–1.898).
Sensitivity analysis considering only patients with con-
firmed therapeutic OAC did not change those results.
The frequency of DWI/Perfusion mismatch was equal
between groups. In those patients with any vessel occlu-
sion, SWI could visualize the thrombus in 19/22 (86%)
of DOAC patients (median 8mm, IQR 6–20) and 57%
of VKA patients (median 13mm, IQR 7–24).
For the secondary outcomes, maximal acute DWI lesion
diameter in DOAC patients (median 18, IQR 11–36) was
equal to VKA (median 20, IQR 7–36) on univariate ana-
lysis (P = 0.607, Table 3). Also, according to the multivari-
able linear regression analysis adjusting for confounders as
outlined in the methods section, VKA was not significantly
associated with increased acute DWI lesion diameter (β
2.385, 95%-CI -10.070 - 14.840, P = 0.705) as compared to
DOAC. Both analyses remained unchanged when only
considering patients with confirmed therapeutic OAC ac-
tivity. There was no difference in the maximal diameter of
the perpendicular axis of the acute ischemic lesion. In
VKA patients, acute DWI lesion diameter was smaller in
the case of confirmed therapeutic OAC activity. For DOAC
patients, this effect could not be seen (Fig. 1).
Size of ischemia lesion diameter at 24 h (FLAIR se-
quence) was equal in DOAC patients (median 18mm,
IQR 12–38) and VKA patients (median 27mm, IQR 8–
50, P = 0.409). The rate of multiple lesions was equal be-
tween groups.
At baseline, 38.9% of DOAC patients and 47.4% of
VKA patients had at least one CMB. One patient (1.3%)
in the DOAC group (Heidelberg class 3) and one patient
(1.6%) in the VKA group (Heidelberg class 2) suffered
symptomatic intracranial hemorrhage at 24 h. 5/75
(6.7%) of DOAC patients and 10/61 (11.5%) of VKA pa-
tients showed asymptomatic hemorrhagic transform-
ation of the ischemic lesion at 24 h.
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Table 1 Baseline characteristics comparing patients with DOAC and VKA pretreatment
DOAC pretreatment
(N = 75)
VKA pretreatment
(N = 61)
P Confirmed therapeutic
DOAC (N = 35)
Confirmed therapeutic
VKA (N = 45)
P
Clinical items
Age (years) 76 (67–82) 81 (75–84) 0.010 76 (68–83) 80 (74–84) 0.117
Body mass index (kg/m2) 26.4 (22.9–29.4) 25.8 (23.6–28.6) 0.674 27.0 (23.1–30.0) 25.7 (23.7–29.3) 0.376
Sex (female) 27/75 (36.0%) 26/61 (42.6%) 0.482 13/35 (37.1%) 20/45 (44.4%) 0.648
Preevent modified Rankin Scale 0.5 (0–1) 1 (0–2) 0.306 0 (0–1) 1 (0–2) 0.327
Onset 0.398 0.407
- Known 34/75 (45.3%) 36/61 (59.0%) 18/35 (51.4%) 29/45 (64.4%)
- Wake-up 14/75 (18.7%) 7/61 (11.5%) 6/35 (17.1%) 4/45 (8.9%)
- Unknown 27/75 (36.0%) 18/61 (29.5%) 11/35 (31.4%) 12/45 (26.7%)
1st blood pressure, systolic 160 (136–176) 160 (146–182) 0.318 156 (135–178) 159 (143–176) 0.446
1st blood pressure, diastolic 79 (70–94) 88 (73–100) 0.089 78 (69–92) 87 (72–99) 0.145
1st Glucose (mmol/L) 6.2 (5.5–7.4) 6.5 (5.5–7.9) 0.500 6.3 (5.7–7.7) 6.6 (5.6–7.9) 0.773
1st Cholesterol, total (mmol/L) 4.4 (3.8–5.1) 4.5 (4.0–5.3) 0.244 4.5 (3.8–5.3) 4.5 (3.8–5.2) 0.848
1st Cholesterol, LDL (mmol/L) 2.4 (1.9–3.2) 2.4 (2.0–3.3) 0.570 2.4 (1.9–3.3) 2.4 (2.1–3.4) 0.587
1st Creatinine (umol/L) 87 (75–102) 88 (72–105) 0.666 89 (75–101) 86 (70–107) 0.809
NIHSS on admission 3 (2–8) 5 (1–10) 0.697 4.5 (2–8.5) 5 (1–12) 0.996
Medication
Additional Antiplatelet 11/75 (14.7%) 11/61 (18.3%) 0.642 3/35 (8.6%) 9/45 (20%) 0.210
Lipid lowering drug 31/75 (41.3%) 26/61 (42.6%) 0.661 16/35 (45.7%) 22/45 (48.9%) 0.824
Anticoagulation
- Confirmed therapeutic 35/75 (46.7%) 45/61 (73.8%)
- Uncertain 30/75 (40%) 0
- Confirmed non-therapeutic 10/75 (13.3%) 16/61 (26.2%)
Risk factors
Previous stroke 22/75 (29.3%) 14/61 (23.0%) 0.626 11/35 (31.4%) 9/45 (20%) 0.239
Previous transient ischemic attack 8/75 (10.7%) 7/61 (11.5%) 0.913 6/35 (17.1%) 6/45 (13.3%) 0.454
Arterial Hypertension 62/75 (82.7%) 53/61 (86.9%) 0.690 28/35 (90%) 40/45 (88.9%) 0.370
Diabetes 15/75 (20.0%) 13/61 (21.3%) 0.957 7/35 (20%) 9/45 (20%) 0.984
Hyperlipidemia 46/75 (61.3%) 41/61 (67.2%) 0.623 19/35 (54.3%) 30/45 (66.7%) 0.192
Smoking 15/75 (20.0%) 4/61 (6.6%) 0.073 7/35 (20%) 2/45 (4.4%) 0.076
Heart failure 11/75 (14.7%) 15/61 (24.6%) 0.328 5/35 (14.3%) 11/45 (24.4%) 0.296
Atrial Fibrillation 52/75 (69.3%) 41/61 (67.2%) 0.617 23/35 (65.7%) 31/45 (68.9%) 0.764
Mechanical Heart Valve 0 4/61 (6.6%) 0.098 0 3/45 (6.7%) 0.135
Low Ejection Fraction (< 30%) 2/75 (2.7%) 1/61 (1.6%) 0.657 1/35 (2.9%) 0 0.437
Peripheral artery disease 8/75 (10.7%) 4/61 (6.6%) 0.677 3/35 (8.6%) 4/45 (8.9%) 0.983
Treatment
Acute recanalization therapy 0.905 0.464
- Intravenous thrombolysis 2/75 (2.7%) 1/61 (1.6%) 1/35 (2.9%) 0
- Endovascular thrombectomy 10/75 (13.3%) 10/61 (16.4%) 3/35 (8.6%) 6/45 (13.3%)
- Intraarterial thrombolysis 1/75 (1.3%) 1/61 (1.6%) 0 1/45 (2.2%)
Imaging
Fazekas Score 1 (0–2) 2 (1–3) < 0.001 1 (0–2) 2 (1–3) 0.014
Cerebral Microbleeds present 28/72 (38.9%) 27/57 (47.4%) 0.373 16/33 (48.5%) 22/42 (52.4%) 0.818
DOAC Direct oral anticoagulant, VKA Vitamin K antagonist, NIHSS National Institute of Health Stroke Scale
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Discussion
The comparison of MRI findings in patients with AIS and
preceding DOAC versus VKA prescription in our real
world university dataset shows the following main findings:
(1) Between DOAC and VKA patients, the frequencies of
any LVO (29.3% versus 37.7%, P = 0.361), and target LVO
for endovascular therapy (26.7% versus 27.9%, P = 1.0; aOR
0.835, 95% CI 0.368–1.898) were equal with a similar occlu-
sion pattern. (2) Also, the presence of multiple lesions and
thrombus characteristics were similar in DOAC and VKA
patients. (3) Ischemic lesion diameter in real world patients
is equal in patients taking DOAC and VKA and this finding
holds true in case of confirmed therapeutic OAC activity.
(4) Lesion size in VKA patients was smaller in the setting
of confirmed therapeutic VKA. (5) The frequency of radio-
logical hemorrhagic transformation and symptomatic intra-
cranial hemorrhage in OAC patients was low.
AIS in the setting of OAC accounts for about 10% of all
AIS in comprehensive stroke centers with rapidly increas-
ing numbers of preceding DOAC prescriptions due to the
increasing number of indications [20, 21]. Besides providing
an accurate diagnosis, neuroimaging aids clinicians in pa-
tient selection for IVT and EVT as well as early medical
management, prognosis assessment and can provide clues
to the etiology of the event and hence guide etiological
work-up.
Our data show that about 1 in 4 patients with preceding
DOAC or VKA has a target LVO for EVT. Macha et al.
reported similar frequencies with a decreasing rate of LVO
with increasing DOAC plasma levels [7]. Fittingly, Woo
et al. reported a LVO rate of 33% in their cohort of 120 AIS
patients with preceding DOAC therapy [8]. The similar oc-
clusion patterns, clot burden and frequency of multiple le-
sions provide insights into the mechanisms associated with
OAC failure and argue for similar stroke etiologies and
pathophysiological mechanisms of thrombus formation
despite different pharmacological modes of action of pre-
ceding VKA and DOAC therapy. In both DOAC and VKA
patients, SWI could visualize the thrombus with a higher
rate in DOAC (86%) as compared to VKA patients
(57%). However, due to the small number of patients,
this difference in sensitivity to detect the thrombus
might be by chance.
Sakamoto et al. found DOAC therapy to be associated
with smaller infarct sizes on MRI in a smaller study (40
non-therapeutic VKA, 22 confirmed therapeutic VKA
and 29 DOAC, 239 controls) [9]. However, the authors
compared non-therapeutic VKA and DOAC treatment
with controls without laboratory assessment of DOAC
activity or information on compliance. Importantly, the
size of infarction for sufficient VKA and DOAC was
comparable in their cohort. Oguro et al. also reported
smaller infarction sizes in a case series of 7 VKA and 10
DOAC patients with recurrent AIS and also found re-
duced ischemia volume with DOAC pretreatment [22].
This study was limited by the small sample size and the
Table 2 Patterns of Large Vessel Occlusions comparing patients with DOAC and VKA pretreatment
DOAC pretreatment
(N = 75)
VKA pretreatment
(N = 61)
P Confirmed therapeutic
DOAC (N = 35)
Confirmed therapeutic
VKA (N = 45)
P
Any large vessel occlusion 22/75 (29.3%) 23/61 (37.7%) 0.361 9/35 (25.7%) 14/45 (31.1%) 0.628
- Proximal ICA 1 (4.5%) 1 (4.3%) 0 0
- Carotid-T 2 (9.1%) 2 (8.7%) 1 (11.1%) 1 (7.1%)
- Proximal M1 7 (31.8%) 4 (17.4%) 3 (33.3%) 1 (7.1%)
- Distal M1 3 (13.6%) 1 (4.3%) 1 (11.1%) 1 (7.1%)
- M2 6 (27.3%) 6 (26.1%) 3 (33.3%) 4 (28.6%)
- M3 0 1 (4.3%) 0 1 (7.1%)
- A1 0 0 0 0
- A2 1 (4.5%) 0 0 0
- V4 0 1 (4.3%) 0 1 (7.1%)
- BA 0 0 0 0
- P1 0 1 (4.3%) 0 1 (7.1%)
- P2/3 1 (4.5%) 4 (17.4%) 0 4 (28.6%)
- Multiple 1 (4.5%) 1 (4.3%) 1 (11.1%) 0
- SCA 0 1 (4.3%) 0 0
Potential target large vessel occlusion for EVT 20/75 (26.7%) 17/61 (27.9%) 1.000 9/35 (25.7%) 9/45 (20.0%) 0.596
DOAC Direct oral anticoagulant, VKA Vitamin K antagonist, ICA Internal carotid artery, M1 M1-segment of medial cerebral artery, M2 M2-segment of medial
cerebral artery, M3 M3-segment of medial cerebral artery, A1 A1-segment of anterior cerebral artery, A2 A2-segment of anterior cerebral artery, V4 V4-segment of
vertebral artery, BA Basilar artery, P1 P1-segment of posterior cerebral artery, P2/3 P2 or P3-segment of posterior cerebral artery, SCA Superior cerebellar artery, EVT
Endovascular stroke treatment
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univariate analysis despite marked baseline differences in
CHA2DS2–VASc score, stroke severity of index event
and renal dysfunction. Our main finding of equal acute
and final infarction diameter in DOAC as compared to
VKA patients fits to recently published data on equal
clinical stroke severity of patients with preceding DOAC
and VKA therapy in real-world patients [16]. Further-
more, the reduced lesion diameter observed in our
study in the setting of confirmed VKA therapy is in
line with previous findings of smaller ischemic lesions
[23] and reduced clinical stroke severity when VKA
therapy is within the target range [24]. Macha et al.
reported reduced stroke severity in the setting of con-
firmed DOAC therapy [7]; however our study might
have lacked power to prove this difference also in
cerebral lesion size.
The low rate of radiological as well as clinically symp-
tomatic intracranial hemorrhage is reassuring; however
recanalization strategies were very infrequently used in
this cohort.
Strengths and limitations
The data was collected prospectively, but our study has
the inherent limitations of a single-center retrospective
analysis. We reliably differentiated between therapeutic
and non-therapeutic OAC in patients prescribed VKA
and DOAC. For assessment of lesion size, we only mea-
sured the diameter and did not use three-dimensional
segmentation tools, which does not accurately reflect
true ischemic lesion size. Nevertheless, the correlation
between maximal diameter and volume seems accept-
able [25] and our main focus was the presence of LVO.
Table 3 Outcome parameter comparing patients with DOAC and VKA pretreatment
DOAC pretreatment
(N = 75)
VKA pretreatment
(N = 61)
P Confirmed therapeutic
DOAC (N = 35)
Confirmed therapeutic
VKA (N = 45)
P
Clinical outcome
NIHSS at 24 h 2 (1–4) 3 (0–7) 0.359 3 (1–5) 4 (0–8) 0.565
sICH ECASS-II 1/75 (1.3%) 1/61 (1.6%) 0.735 0 1/45 (2.2%) 0.298
Duration of hospital stay, days 4 (2–8) 4 (2–8) 0.345 4 (3–7) 4 (2–8) 0.359
90d mRS 1.5 (1–3) 3 (1.5–4) 0.001 1 (1–2) 3 (2–6) < 0.001
90d recurrent stroke 2/75 (2.7%) 4/61 (6.6%) 0.255 0 3/45 (6.7%) 0.185
Imaging
Diameter axis 1, initial DWI, mm 18 (11–36) 20 (7–36) 0.607 19 (12–33) 13 (6–26) 0.111
Diameter axis 2, initial DWI, mm 10 (6–19) 9 (5–23) 0.780 12 (6–19) 7 (4–16) 0.127
Diameter hypoperfusion axis 1, mm 80 (38–118), N = 40 49 (36–67), N = 37 0.039 83 (27–118), N = 16 49 (36–66), N = 13 0.079
Diameter hypoperfusion axis 2, mm 34 (18–40), N = 40 34 (14–40), N = 37 0.494 34 (20–46), N = 16 33 (13–38), N = 13 0.318
DWI/Perfusion Mismatch 0.443 0.714
- None 39/66 (59.1%) 29/53 (54.7%) 17/28 (60.7%) 26/40 (65.0%)
- Small 4/66 (6.1%) 8/53 (15.1%) 1/28 (3.6%) 3/40 (7.5%)
- Medium 4/66 (6.1%) 3/53 (5.7%) 2/28 (7.1%) 1/40 (2.5%)
- Large 19/66 (28.8%) 13/53 (24.5%) 8/28 (28.6%) 10/40 (25%)
Diameter axis 1, final FLAIR 18 (12–38) 27 (8–50) 0.409 18 (13–23) 20 (6–52) 0.945
Diameter axis 2, final FLAIR 10 (6–22) 14 (7–25) 0.397 10 (6–22) 11 (5–25) 0.908
Occlusion, any 22/75 (29.3%) 23/61 (37.7%) 0.361 9/35 (25.7%) 14/45 (31.1%) 0.628
Target occlusion for EVT 20/75 (26.7%) 17/61 (27.9%) 1.000 9/35 (25.7%) 9/45 (20.0%) 0.596
Thrombus length 8 (6–20), N = 19 13 (7–24), N = 13 0.388 15 (6–21), N = 7 11 (4–30), N = 6 0.836
Multiple Lesions 31/56 (55.4%) 24/49 (49.0%) 0.560 10/21 (47.6%) 20/41 (48.8%) 1.000
ICH, Heidelberg at follow up 0.024 0.126
- 1a 5/75 (6.7%) 3/61 (4.9%) 4/35 (11.4%) 3/45 (6.7%)
- 1b 0 7/61 (11.5%) 0 5/45 (11.1%)
- 2 0 1/61 (1.6%) 0 0
- 3c 1/75 (1.3%) 0 1 (2.9%) 0
DOAC Direct oral anticoagulant, VKA Vitamin K antagonist, NIHSS National Institute of Health Stroke Scale, sICH ECASS II symptomatic intracranial hemorrhage
according to the European Co-operative Acute Stroke Study-II definition, mRS modified Rankin Scale, DWI Diffusion weighted imaging, FLAIR Fluid attenuated
inversion recovery sequence, EVT Endovascular stroke treatment, ICH Intracranial hemorrhage
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The cutoff of 1/3 used in the mismatch analysis was ar-
bitrary and might not be easily comparable to more
commonly used cutoffs such as > 20% of the ischemic le-
sion. Although baseline characteristics of the DOAC and
VKA group were almost identical, we might have missed
confounding baseline variables influencing the physi-
cians’ indication of DOAC/VKA and affecting imaging
outcomes. Due to the limited number of patients with
DOAC other than Rivaroxaban, our findings should not
be extrapolated to those substances. Therefore, the find-
ings have to be replicated in further cohorts.
Conclusion
In conclusion, we found that about 1 in 4 patients with
preceding OAC has a target LVO for EVT. The ischemic
lesion size was equal in patients taking DOAC and VKA,
also in the setting of confirmed therapeutic OAC activ-
ity. Since imaging features are similar, the mechanisms
associated with AIS despite preceding DOAC or VKA
treatment seem alike.
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